{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:13:27Z","timestamp":1784042007432,"version":"3.55.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02185-1","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:46:28Z","timestamp":1779288388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["White adipose tissue expansion as the driver of insulin resistance and secondary endocrine disturbances in obesity\u2013 a narrative review"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-5249","authenticated-orcid":false,"given":"Marta","family":"Dobrzycka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Karczewska-Kupczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2185_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020368","volume":"13","author":"M Jani\u0107","year":"2025","unstructured":"Jani\u0107 M, Jane\u017e A, El-Tanani M, Rizzo M. Obesity: recent advances and future perspectives. Biomedicines. 2025;13:368.","journal-title":"Biomedicines"},{"key":"2185_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00022","volume":"7","author":"A Chait","year":"2020","unstructured":"Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22.","journal-title":"Front Cardiovasc Med"},{"key":"2185_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4\u00a0million participants. Lancet. 2016;387:1513\u201330.","journal-title":"Lancet"},{"key":"2185_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcp.21386","volume":"216","author":"P Wang","year":"2008","unstructured":"Wang P, Mariman E, Renes J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 2008;216:3\u201313.","journal-title":"J Cell Physiol"},{"key":"2185_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-63260-5_1","volume":"19","author":"P Matafome","year":"2017","unstructured":"Matafome P, Sei\u00e7a R. Function and dysfunction of adipose tissue. Adv Neurobiol. 2017;19:3\u201331.","journal-title":"Adv Neurobiol"},{"key":"2185_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000471488","volume":"10","author":"GH Goossens","year":"2017","unstructured":"Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10:207\u201315.","journal-title":"Obes Facts"},{"key":"2185_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/msj.20212","volume":"77","author":"EJ Gallagher","year":"2010","unstructured":"Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010;77:511\u201323.","journal-title":"Mt Sinai J Med"},{"key":"2185_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4093\/dmj.2012.36.6.391","volume":"36","author":"JH Yu","year":"2012","unstructured":"Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J. 2012;36:391\u20138.","journal-title":"Diabetes Metab J"},{"key":"2185_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-19-0666","volume":"182","author":"LT van Hulsteijn","year":"2020","unstructured":"van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. Eur J Endocrinol. 2020;182:11\u201321.","journal-title":"Eur J Endocrinol"},{"key":"2185_CR10","unstructured":"Ylli D, Sidhu S, Parikh T, et al. Endocrine changes in obesity. In: Feingold KR, Anawalt B, Boyce A, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.Available from: [Updated 2022 Sep 6] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279053\/"},{"key":"2185_CR11","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-19-0893","volume":"182","author":"R Pasquali","year":"2020","unstructured":"Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol. 2020;182:G1\u201332.","journal-title":"Eur J Endocrinol"},{"key":"2185_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133\u2013223.","journal-title":"Physiol Rev"},{"key":"2185_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/13813450600736174","volume":"112","author":"L Laviola","year":"2006","unstructured":"Laviola L, Perrini S, Cignarelli A, Giorgino F. Insulin signalling in human adipose tissue. Arch Physiol Biochem. 2006;112:82\u20138.","journal-title":"Arch Physiol Biochem"},{"key":"2185_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1872214810666161020154905","volume":"10","author":"V Sidarala","year":"2017","unstructured":"Sidarala V, Kowluru A. The regulatory roles of mitogen-activated protein kinase (MAPK) pathways in health and diabetes: lessons learned from the pancreatic \u03b2-Cell. Recent Pat Endocr Metab Immune Drug Discov. 2017;10:76\u201384.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"2185_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12967-019-1919-y","volume":"17","author":"A De Lorenzo","year":"2019","unstructured":"De Lorenzo A, Gratteri S, Gualtieri P, et al. Why primary obesity is a disease? J Transl Med. 2019;17:169.","journal-title":"J Transl Med"},{"key":"2185_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1748-1716.2012.02409.x","volume":"205","author":"A Wronska","year":"2012","unstructured":"Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf). 2012;205:194\u2013208.","journal-title":"Acta Physiol (Oxf)"},{"key":"2185_CR17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00125-016-3933-4","volume":"59","author":"V Pellegrinelli","year":"2016","unstructured":"Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia. 2016;59:1075\u201388.","journal-title":"Diabetologia"},{"issue":"12","key":"2185_CR18","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796\u2013808.","journal-title":"J Clin Invest"},{"key":"2185_CR19","first-page":"1245","volume":"70","author":"N Matulewicz","year":"2016","unstructured":"Matulewicz N, Karczewska-Kupczewska M. Insulin resistance and chronic inflammation. Postepy Hig Med Dosw. 2016;70:1245\u201358.","journal-title":"Postepy Hig Med Dosw"},{"key":"2185_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1096\/fsb2fj000435fje","volume":"15","author":"E Carvalho","year":"2001","unstructured":"Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U. Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. FASEB J. 2001;15:1101\u20133.","journal-title":"FASEB J"},{"key":"2185_CR21","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1210\/jc.2017-00597","volume":"102","author":"N Matulewicz","year":"2017","unstructured":"Matulewicz N, Stefanowicz M, Nikolajuk A, Karczewska-Kupczewska M. Markers of adipogenesis, but not inflammation, in adipose tissue are independently related to insulin sensitivity. J Clin Endocrinol Metab. 2017;102:3040\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fendo.2013.00037","volume":"4","author":"ME Cerf","year":"2013","unstructured":"Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2185_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-35525-2","volume":"16","author":"D Fotros","year":"2026","unstructured":"Fotros D, Hekmatdoost A, Yari Z. Obesity as a predictor of atherogenic dyslipidemia in patients with metabolic dysfunction associated steatotic liver disease. Sci Rep. 2026;16:6209.","journal-title":"Sci Rep"},{"key":"2185_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12944-018-0856-8","volume":"17","author":"O Gruzdeva","year":"2018","unstructured":"Gruzdeva O, Borodkina D, Uchasova E, et al. Localization of fat depots and cardiovascular risk. Lipids Health Dis. 2018;17:218.","journal-title":"Lipids Health Dis"},{"key":"2185_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2013.12.023","volume":"233","author":"N Alexopoulos","year":"2014","unstructured":"Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233:104\u201312.","journal-title":"Atherosclerosis"},{"key":"2185_CR26","doi-asserted-by":"crossref","unstructured":"Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients., Tchernof A, Despr\u00e9s JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359\u2013404.","DOI":"10.1152\/physrev.00033.2011"},{"key":"2185_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof A, Despr\u00e9s JP. Pathophysiology of humanvisceral obesity: an update. Physiol Rev. 2013;93:359\u2013404.","journal-title":"Physiol Rev."},{"key":"2185_CR28","doi-asserted-by":"publisher","first-page":"18495","DOI":"10.1038\/srep18495","volume":"5","author":"M Zhang","year":"2015","unstructured":"Zhang M, Hu T, Zhang S, et al. Associations of different adipose tissue depots with insulin resistance: a systematic review and meta-analysis of observational studies. Sci Rep. 2015;5:18495.","journal-title":"Sci Rep"},{"key":"2185_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ijo.2009.286","volume":"34","author":"KN Manolopoulos","year":"2010","unstructured":"Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes. 2010;34:949\u201359.","journal-title":"Int J Obes"},{"key":"2185_CR30","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/oby.2010.59","volume":"18","author":"SR Preis","year":"2010","unstructured":"Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obes (Silver Spring). 2010;18:2191\u20138.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jacc.2014.05.057","volume":"64","author":"A Chandra","year":"2014","unstructured":"Chandra A, Neeland IJ, Berry JD, et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014;64:997\u20131002.","journal-title":"J Am Coll Cardiol"},{"key":"2185_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/oby.20135","volume":"21","author":"IJ Neeland","year":"2013","unstructured":"Neeland IJ, Ayers CR, Rohatgi AK, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obes (Silver Spring). 2013;21:439\u201347.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/oby.2006.43","volume":"14","author":"JL Kuk","year":"2006","unstructured":"Kuk JL, Katzmarzyk PT, Nichaman MZ, et al. Visceral fat is an independent predictor of all-cause mortality in men. Obes (Silver Spring). 2006;14:336\u201341.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/oby.21028","volume":"23","author":"A Koster","year":"2015","unstructured":"Koster A, Murphy RA, Eiriksdottir G, et al. Fat distribution and mortality: the AGES-Reykjavik Study. Obes (Silver Spring). 2015;23:893\u20137.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/sj.ijo.0802567","volume":"28","author":"PZ Zimmet","year":"2004","unstructured":"Zimmet PZ, Visser M, et al. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord. 2004;28:402\u20139.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2185_CR36","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","volume":"366","author":"S Yusuf","year":"2005","unstructured":"Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640\u20139.","journal-title":"Lancet"},{"key":"2185_CR37","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00125-021-05484-6","volume":"64","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Macpherson J, Gray SR, et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia. 2021;64:1963\u201372.","journal-title":"Diabetologia"},{"key":"2185_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/joim.12540","volume":"280","author":"U Smith","year":"2016","unstructured":"Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280:465\u201375.","journal-title":"J Intern Med"},{"key":"2185_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nature06902","volume":"453","author":"KL Spalding","year":"2008","unstructured":"Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783\u20137.","journal-title":"Nature"},{"key":"2185_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2337\/db09-0942","volume":"59","author":"E Arner","year":"2010","unstructured":"Arner E, Westermark PO, Spalding KL, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes. 2010;59:105\u20139.","journal-title":"Diabetes"},{"key":"2185_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.cmet.2014.10.010","volume":"20","author":"SM Kim","year":"2014","unstructured":"Kim SM, Lun M, Wang M, et al. Loss of white adipose hyperplastic potential is associated with enhanced susceptibility to insulin resistance. Cell Metab. 2014;20:1049\u201358.","journal-title":"Cell Metab"},{"key":"2185_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2337\/db10-1039","volume":"60","author":"A Veilleux","year":"2011","unstructured":"Veilleux A, Caron-Jobin M, No\u00ebl S, et al. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes. 2011;60:1504\u201311.","journal-title":"Diabetes"},{"key":"2185_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tem.2015.01.006","volume":"26","author":"B Gustafson","year":"2015","unstructured":"Gustafson B, Hedjazifar S, Gogg S, et al. Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab. 2015;26:193\u2013200.","journal-title":"Trends Endocrinol Metab"},{"key":"2185_CR44","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1007\/s11695-020-04983-6","volume":"30","author":"F Liu","year":"2020","unstructured":"Liu F, He J, Wang H, et al. Adipose Morphology: a Critical Factor in Regulation of Human Metabolic Diseases and Adipose Tissue Dysfunction. Obes Surg. 2020;30:5086\u2013100.","journal-title":"Obes Surg"},{"key":"2185_CR45","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/ijms20092358","volume":"20","author":"M Longo","year":"2019","unstructured":"Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019;20:2358.","journal-title":"Int J Mol Sci"},{"key":"2185_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00125-015-3810-6","volume":"59","author":"JR Acosta","year":"2016","unstructured":"Acosta JR, Douagi I, Andersson DP, et al. Increased fat cell size: a major phenotype of subcutaneous white adipose tissue in non-obese individuals with type 2 diabetes. Diabetologia. 2016;59:560\u201370.","journal-title":"Diabetologia"},{"key":"2185_CR47","doi-asserted-by":"publisher","first-page":"e105262","DOI":"10.1371\/journal.pone.0105262","volume":"9","author":"AM Henninger","year":"2014","unstructured":"Henninger AM, Eliasson B, Jenndahl LE, et al. Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. PLoS ONE. 2014;9:e105262.","journal-title":"PLoS ONE"},{"key":"2185_CR48","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.clinbiochem.2012.07.097","volume":"45","author":"F Monickaraj","year":"2012","unstructured":"Monickaraj F, Gokulakrishnan K, Prabu P, et al. Convergence of adipocyte hypertrophy, telomere shortening and hypoadiponectinemia in obese subjects and in patients with type 2 diabetes. Clin Biochem. 2012;45:1432\u20138.","journal-title":"Clin Biochem"},{"key":"2185_CR49","doi-asserted-by":"publisher","first-page":"e108421","DOI":"10.1371\/journal.pone.0108421","volume":"9","author":"VP Meena","year":"2014","unstructured":"Meena VP, Seenu V, Sharma MC, et al. Relationship of adipocyte size with adiposity and metabolic risk factors in Asian Indians. PLoS One. 2014;9:e108421.","journal-title":"PLoS One"},{"key":"2185_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/oby.21377","volume":"24","author":"LA Muir","year":"2016","unstructured":"Muir LA, Neeley CK, Meyer KA, et al. Adipose tissue fibrosis, hypertrophy, and hyperplasia: Correlations with diabetes in human obesity. Obes (Silver Spring). 2016;24:597\u2013605.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR51","doi-asserted-by":"publisher","first-page":"e9997","DOI":"10.1371\/journal.pone.0009997","volume":"5","author":"J O\u2019Connell","year":"2010","unstructured":"O\u2019Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS ONE. 2010;5:e9997.","journal-title":"PLoS ONE"},{"key":"2185_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.atherosclerosis.2015.01.035","volume":"239","author":"ME Kranendonk","year":"2015","unstructured":"Kranendonk ME, van Herwaarden JA, Stupkova T, et al. Inflammatory characteristics of distinct abdominal adipose tissue depots relate differently to metabolic risk factors for cardiovascular disease: distinct fat depots and vascular risk factors. Atherosclerosis. 2015;239:419\u201327.","journal-title":"Atherosclerosis"},{"key":"2185_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/21623945.2017.1287639","volume":"6","author":"LA Muir","year":"2017","unstructured":"Muir LA, Baker NA, Washabaugh AR, et al. Adipocyte hypertrophy-hyperplasia balance contributes to weight loss after bariatric surgery. Adipocyte. 2017;6:134\u201340.","journal-title":"Adipocyte"},{"key":"2185_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/obr.12255","volume":"16","author":"PS MacLean","year":"2015","unstructured":"MacLean PS, Higgins JA, Giles ED, et al. The role for adipose tissue in weight regain after weight loss. Obes Rev. 2015;16:45\u201354.","journal-title":"Obes Rev"},{"key":"2185_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.numecd.2018.09.014","volume":"29","author":"T McLaughlin","year":"2019","unstructured":"McLaughlin T, Abbasi F, Lamendola C, et al. Dietary weight loss in insulin-resistant non-obese humans: metabolic benefits and relationship to adipose cell size. Nutr Metab Cardiovasc Dis. 2019;29:62\u20138.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2185_CR56","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2337\/dc13-2395","volume":"37","author":"DP Andersson","year":"2014","unstructured":"Andersson DP, Eriksson Hogling D, Thorell A, et al. Changes in subcutaneous fat cell volume and insulin sensitivity after weight loss. Diabetes Care. 2014;37:1831\u20136.","journal-title":"Diabetes Care"},{"key":"2185_CR57","doi-asserted-by":"publisher","first-page":"18226","DOI":"10.1073\/pnas.1005259107","volume":"107","author":"YD Tchoukalova","year":"2010","unstructured":"Tchoukalova YD, Votruba SB, Tchkonia T, et al. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A. 2010;107:18226\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2185_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3945\/ajcn.111.033829","volume":"96","author":"P Singh","year":"2012","unstructured":"Singh P, Somers VK, Romero-Corral A, et al. Effects of weight gain and weight loss on regional fat distribution. Am J Clin Nutr. 2012;96:229\u201333.","journal-title":"Am J Clin Nutr"},{"key":"2185_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1152\/ajpendo.00044.2017","volume":"313","author":"P Dadson","year":"2017","unstructured":"Dadson P, Ferrannini E, Landini L, et al. Fatty acid uptake and blood flow in adipose tissue compartments of morbidly obese subjects with or without type 2 diabetes: effects of bariatric surgery. Am J Physiol Endocrinol Metab. 2017;313:175\u201382.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2185_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13287-015-0029-x","volume":"6","author":"KR Silva","year":"2015","unstructured":"Silva KR, Liechocki S, Carneiro JR, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. Stem Cell Res Ther. 2015;6:72.","journal-title":"Stem Cell Res Ther"},{"key":"2185_CR61","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1096\/fj.12-207217","volume":"26","author":"B O\u00f1ate","year":"2012","unstructured":"O\u00f1ate B, Vilahur G, Ferrer-Lorente R, et al. The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. FASEB J. 2012;26:4327\u201336.","journal-title":"FASEB J"},{"key":"2185_CR62","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2337\/db08-1770","volume":"58","author":"P Isakson","year":"2009","unstructured":"Isakson P, Hammarstedt A, Gustafson B, et al. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009;58:1550\u20137.","journal-title":"Diabetes"},{"key":"2185_CR63","doi-asserted-by":"publisher","first-page":"e0174115","DOI":"10.1371\/journal.pone.0174115","volume":"12","author":"KR Silva","year":"2017","unstructured":"Silva KR, C\u00f4rtes I, Liechocki S, et al. Characterization of stromal vascular fraction and adipose stem cells from subcutaneous, preperitoneal and visceral morbidly obese human adipose tissue depots. PLoS One. 2017;12:e0174115.","journal-title":"PLoS One"},{"key":"2185_CR64","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/oby.21053","volume":"23","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Tchkonia T, Stout MB, et al. Inflammation and the depot-specific secretome of human preadipocytes. Obesity (Silver Spring). 2015;23:989\u201399.","journal-title":"Obesity (Silver Spring)"},{"key":"2185_CR65","doi-asserted-by":"publisher","first-page":"e57892","DOI":"10.1371\/journal.pone.0057892","volume":"8","author":"S Perrini","year":"2013","unstructured":"Perrini S, Ficarella R, Picardi E, et al. Differences in gene expression and cytokine release profiles highlight the heterogeneity of distinct subsets of adipose tissue-derived stem cells in the subcutaneous and visceral adipose tissue in humans. PLoS One. 2013;8:e57892.","journal-title":"PLoS One"},{"key":"2185_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0029-x","volume":"6","author":"KR Silva","year":"2015","unstructured":"Silva KR, Liechocki S, Carneiro JR, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. Stem Cell Res Ther. 2015;6:72.","journal-title":"Stem Cell Res Ther"},{"key":"2185_CR67","first-page":"453","volume":"83","author":"MF Saad","year":"1998","unstructured":"Saad MF, Riad-Gabriel MG, Khan A, et al. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab. 1998;83:453\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR68","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/35078085","volume":"411","author":"MA Cowley","year":"2001","unstructured":"Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411:480\u20134.","journal-title":"Nature"},{"key":"2185_CR69","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrendo.2014.91","volume":"10","author":"S Murray","year":"2014","unstructured":"Murray S, Tulloch A, Gold MS, et al. Hormonal and neural mechanisms of food reward, eating behaviour and obesity. Nat Rev Endocrinol. 2014;10:540\u201352.","journal-title":"Nat Rev Endocrinol"},{"key":"2185_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fendo.2018.00089","volume":"9","author":"S Fruhw\u00fcrth","year":"2018","unstructured":"Fruhw\u00fcrth S, Vogel H, Sch\u00fcrmann A, et al. Novel Insights into How Overnutrition Disrupts the Hypothalamic Actions of Leptin. Front Endocrinol (Lausanne). 2018;9:89.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2185_CR71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/2230-8210.105571","volume":"16","author":"G Paz-Filho","year":"2012","unstructured":"Paz-Filho G, Mastronardi C, Wong ML, et al. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 2012;16:549\u201355.","journal-title":"Indian J Endocrinol Metab"},{"key":"2185_CR72","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/nm0995-950","volume":"1","author":"F Lonnqvist","year":"1995","unstructured":"Lonnqvist F, Arner P, Nordfors L, et al. Overexpression of the Obese (Ob) Gene in Adipose Tissue of Human Obese Subjects. Nat Med. 1995;1:950\u20133.","journal-title":"Nat Med"},{"key":"2185_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/CPT.S116242","volume":"7","author":"JT Kiehn","year":"2017","unstructured":"Kiehn JT, Koch CE, Walter M, et al. Circadian rhythms and clocks in adipose tissues: current insights. ChronoPhysiology Therapy. 2017;7:7\u201317.","journal-title":"ChronoPhysiology Therapy"},{"key":"2185_CR74","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199602013340503","volume":"334","author":"RV Considine","year":"1996","unstructured":"Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292\u20135.","journal-title":"N Engl J Med"},{"key":"2185_CR75","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.2337\/db10-1302","volume":"60","author":"B Mittendorfer","year":"2011","unstructured":"Mittendorfer B, Horowitz JF, DePaoli AM, et al. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes. 2011;60:1474\u20137.","journal-title":"Diabetes"},{"key":"2185_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.ijo.0801952","volume":"26","author":"CJ Hukshorn","year":"2002","unstructured":"Hukshorn CJ, van Dielen FM, Buurman WA, et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord. 2002;26:504\u20139.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2185_CR77","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","volume":"85","author":"CJ Hukshorn","year":"2000","unstructured":"Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab. 2000;85:4003\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR78","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/oby.20433","volume":"21","author":"J Korner","year":"2013","unstructured":"Korner J, Conroy R, Febres G, et al. Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obes (Silver Spring). 2013;21:951\u20136.","journal-title":"Obes (Silver Spring)"},{"issue":"2","key":"2185_CR79","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1210\/clinem\/dgad505","volume":"109","author":"M Chiriac\u00f2","year":"2024","unstructured":"Chiriac\u00f2 M, Nesti L, Flyvbjerg A, et al. At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated With Decreased Insulin Sensitivity. J Clin Endocrinol Metab. 2024;109(2):461\u201370.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s005920200027","volume":"39","author":"S Fischer","year":"2002","unstructured":"Fischer S, Hanefeld M, Haffner SM, et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002;39:105\u201310.","journal-title":"Acta Diabetol"},{"key":"2185_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/diacare.22.1.65","volume":"22","author":"MJ McNeely","year":"1999","unstructured":"McNeely MJ, Boyko EJ, Weigle DS, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999;22:65\u201370.","journal-title":"Diabetes Care"},{"key":"2185_CR82","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/DMSO.S182406","volume":"12","author":"O Gruzdeva","year":"2019","unstructured":"Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019;12:191\u20138.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2185_CR83","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/JLB.MR1218-478R","volume":"106","author":"L Monteiro","year":"2019","unstructured":"Monteiro L, Pereira JADS, Palhinha L, Moraes-Vieira PMM. Leptin in the regulation of the immunometabolism of adipose tissue-macrophages. J Leukoc Biol. 2019;106:703\u201316.","journal-title":"J Leukoc Biol"},{"key":"2185_CR84","doi-asserted-by":"crossref","unstructured":"Mazzali G, Di Francesco V, Zoico E, Fantin F Interrelations between fat distribution, muscle lipid content, adipocytokines, and insulin resistance: effect of moderate weight loss in older women. Am J Clin Nutr., Chang TM, Lee WJ et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring). 2008;16:1033\u20131038.","DOI":"10.1038\/oby.2008.37"},{"key":"2185_CR85","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/oby.2008.37","volume":"16","author":"WH Sheu","year":"2008","unstructured":"Sheu WH, Chang TM, Lee WJ, et al. Effect of weight loss on proinflammatory state of mononuclear cells inobese women. Obesity (Silver Spring). 2008;16:1033\u20138.","journal-title":"Obesity (Silver Spring)."},{"key":"2185_CR86","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.kjms.2012.08.041","volume":"29","author":"TN Wang","year":"2013","unstructured":"Wang TN, Chang WT, Chiu YW, et al. Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss. Kaohsiung J Med Sci. 2013;29:436\u201343.","journal-title":"Kaohsiung J Med Sci"},{"key":"2185_CR87","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1210\/jc.2009-2566","volume":"95","author":"AB Crujeiras","year":"2010","unstructured":"Crujeiras AB, Goyenechea E, Abete I, et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab. 2010;95:5037\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR88","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000281833","volume":"56","author":"A Ramel","year":"2010","unstructured":"Ramel A, Arnarson A, Parra D, et al. Gender difference in the prediction of weight loss by leptin among overweight adults. Ann Nutr Metab. 2010;56:190\u20137.","journal-title":"Ann Nutr Metab"},{"key":"2185_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2302\/kjm.60.1","volume":"60","author":"JM Friedman","year":"2011","unstructured":"Friedman JM. Leptin and the regulation of body weight. Keio J Med. 2011;60:1\u20139.","journal-title":"Keio J Med"},{"key":"2185_CR90","first-page":"4197","volume":"84","author":"JS Torgerson","year":"1999","unstructured":"Torgerson JS, Carlsson B, Stenlof K, et al. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab. 1999;84:4197\u2013203.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR91","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3945\/ajcn.110.002212","volume":"93","author":"SB Murer","year":"2011","unstructured":"Murer SB, Kn\u00f6pfli BH, Aeberli I, et al. Baseline leptin and leptin reduction predict improvements in metabolic variables and long-term fat loss in obese children and adolescents: a prospective study of an inpatient weight-loss program. Am J Clin Nutr. 2011;93:695\u2013702.","journal-title":"Am J Clin Nutr"},{"key":"2185_CR92","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.psyneuen.2012.10.021","volume":"38","author":"P Monteleone","year":"2013","unstructured":"Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. Psychoneuroendocrinology. 2013;38:312\u201330.","journal-title":"Psychoneuroendocrinology"},{"key":"2185_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.13385","volume":"20","author":"T Napolitano","year":"2018","unstructured":"Napolitano T, Silvano S, Vieira A, et al. Role of ghrelin in pancreatic development and function. Diabetes Obes Metab. 2018;20:3\u201310.","journal-title":"Diabetes Obes Metab"},{"key":"2185_CR94","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1096\/fj.11-183632","volume":"25","author":"D Perez-Tilve","year":"2011","unstructured":"Perez-Tilve D, Heppner K, Kirchner H, Lockie SH, Woods SC, Smiley DL, Tsch\u00f6p M, Pfluger P. Ghrelin-induced adiposity is independent of orexigenic effects. FASEB J. 2011;25:2814\u201322.","journal-title":"FASEB J"},{"key":"2185_CR95","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/obr.12474","volume":"18","author":"R Churm","year":"2017","unstructured":"Churm R, Davies JS, Stephens JW, et al. Ghrelin function in human obesity and type 2 diabetes: a concise review. Obes Rev. 2017;18:140\u20138.","journal-title":"Obes Rev"},{"key":"2185_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01308","volume":"9","author":"CS Zhang","year":"2018","unstructured":"Zhang CS, Wang LX, Wang R, et al. The correlation between circulating Ghrelin and insulin resistance in obesity: a meta-analysis. Front Physiol. 2018;9:1308.","journal-title":"Front Physiol"},{"key":"2185_CR97","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1210\/jc.2003-031572","volume":"89","author":"T McLaughlin","year":"2004","unstructured":"McLaughlin T, Abbasi F, Lamendola C, et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab. 2004;89:1630\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tem.2015.09.010","volume":"27","author":"JM Zigman","year":"2016","unstructured":"Zigman JM, Bouret SG, Andrews ZB. Obesity impairs the action of the neuroendocrine Ghrelin system. Trends Endocrinol. 2016;27:54\u201363.","journal-title":"Trends Endocrinol"},{"key":"2185_CR99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/dom.14274","volume":"23","author":"G Thom","year":"2021","unstructured":"Thom G, McIntosh A, Messow CM, et al. Weight loss induced increase in fasting ghrelin concentration is a predictor of weight regain: evidence from the Diabetes Remission Clinical Trial. Diabetes Obes Metab. 2021;23:711\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2185_CR100","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.tjnut.2023.12.043","volume":"154","author":"M Karczewska-Kupczewska","year":"2024","unstructured":"Karczewska-Kupczewska M, Stefanowicz M, Niko\u0142ajuk A, Str\u0105czkowski M. Weight-reducing dietary intervention increases the ability of hyperinsulinemia to suppress serum Ghrelin concentration in individuals with obesity. J Nutr. 2024;154:1631\u20139.","journal-title":"J Nutr"},{"key":"2185_CR101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20:5\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"2185_CR102","first-page":"473","volume":"9","author":"GA Boer","year":"2020","unstructured":"Boer GA, Holst JJ. Incretin hormones and Type 2 Diabetes-mechanistic insights and therapeutic approaches. Biology (Basel). 2020;9:473.","journal-title":"Biology (Basel)"},{"key":"2185_CR103","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1210\/en.2011-1070","volume":"152","author":"J Vendrell","year":"2011","unstructured":"Vendrell J, El Bekay R, Peral B, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152:4072\u20139.","journal-title":"Endocrinology"},{"issue":"1","key":"2185_CR104","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1038\/s41598-019-42770-1","volume":"18","author":"M Ejarque","year":"2019","unstructured":"Ejarque M, Guerrero-P\u00e9rez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with Type 2 Diabetes. Sci Rep. 2019;18:6274.","journal-title":"Sci Rep"},{"key":"2185_CR105","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23:5\u201329.","journal-title":"Diabetes Obes Metab"},{"key":"2185_CR106","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1210\/jc.2013-3350","volume":"99","author":"V Ceperuelo-Mallafr\u00e9","year":"2014","unstructured":"Ceperuelo-Mallafr\u00e9 V, Duran X, Pach\u00f3n G, et al. Disruption of GIP\/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab. 2014;99:908\u201319.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR107","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.2337\/dc13-0465","volume":"36","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care. 2013;36:3346\u201352.","journal-title":"Diabetes Care"},{"key":"2185_CR108","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","volume":"56","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965\u201372.","journal-title":"Diabetologia"},{"key":"2185_CR109","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with Type 2 Diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2185_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0\u00a0mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"2185_CR111","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, et al. SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399\u2013409.","journal-title":"Lancet"},{"key":"2185_CR112","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/00325481.2022.2147325","volume":"134","author":"A Amaro","year":"2022","unstructured":"Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022;134:18\u201327.","journal-title":"Postgrad Med"},{"key":"2185_CR113","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392:427\u201337.","journal-title":"N Engl J Med"},{"key":"2185_CR114","doi-asserted-by":"publisher","first-page":"e0270899","DOI":"10.1371\/journal.pone.0270899","volume":"17","author":"F Liu","year":"2022","unstructured":"Liu F, Yang Q, Zhang H, et al. The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS One. 2022;17:e0270899.","journal-title":"PLoS One"},{"key":"2185_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769069","volume":"12","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu J, Zhang D, et al. Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol. 2021;12:769069.","journal-title":"Front Endocrinol"},{"key":"2185_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102562","volume":"16","author":"G Berg","year":"2022","unstructured":"Berg G, Barchuk M, Lobo M, et al. Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: a meta-analysis. Diabetes Metab Syndr. 2022;16:102562.","journal-title":"Diabetes Metab Syndr"},{"key":"2185_CR117","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14908","volume":"25","author":"F He","year":"2023","unstructured":"He F, Chen W, Xu W, et al. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2023;25:664\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"2185_CR118","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4158\/EP14072.OR","volume":"20","author":"SY Lee","year":"2014","unstructured":"Lee SY, Braverman LE, Pearce EN. Changes in body weight after treatment of primary hypothyroidism with levothyroxine. Endocr Pract. 2014;20:1122\u20138.","journal-title":"Endocr Pract"},{"key":"2185_CR119","first-page":"157","volume":"10","author":"LH Duntas","year":"2014","unstructured":"Duntas LH, Chiovato L. Cardiovascular risk in patients with subclinical hypothyroidism. Eur Endocrinol. 2014;10:157\u201360.","journal-title":"Eur Endocrinol"},{"key":"2185_CR120","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/0003-4819-132-4-200002150-00004","volume":"132","author":"AE Hak","year":"2000","unstructured":"Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270\u20138.","journal-title":"Ann Intern Med"},{"key":"2185_CR121","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/sj.ijo.0803112","volume":"30","author":"A Nyrnes","year":"2006","unstructured":"Nyrnes A, Jorde R, Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes. 2006;30:100\u20135.","journal-title":"Int J Obes"},{"key":"2185_CR122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/thy.2006.16.73","volume":"16","author":"MA Michalaki","year":"2006","unstructured":"Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16:73\u20138.","journal-title":"Thyroid"},{"key":"2185_CR123","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2007.02874.x","volume":"67","author":"G De Pergola","year":"2007","unstructured":"De Pergola G, Ciampolillo A, Paolotti S, et al. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol (Oxf). 2007;67:265\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2185_CR124","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/thy.2021.0351","volume":"32","author":"M Straczkowski","year":"2022","unstructured":"Straczkowski M, Nikolajuk A, Stefanowicz M, et al. Adipose Tissue and Skeletal Muscle Expression of Genes Associated with Thyroid Hormone Action in Obesity and Insulin Resistance. Thyroid. 2022;32:206\u201314.","journal-title":"Thyroid"},{"issue":"3","key":"2185_CR125","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.diabet.2014.11.009","volume":"41","author":"C B\u00e9try","year":"2015","unstructured":"B\u00e9try C, Challan-Belval MA, Bernard A, Charri\u00e9 A, Drai J, Laville M, et al. Increased TSH in obesity: evidence for a BMI-independent association with leptin. Diabetes Metab. 2015;41(3):248\u201351.","journal-title":"Diabetes Metab"},{"key":"2185_CR126","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ijo.2009.140","volume":"33","author":"M Nannipieri","year":"2009","unstructured":"Nannipieri M, Cecchetti F, Anselmino M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and\/or type 2 diabetes: Effects of weight loss. Int J Obes (Lond). 2009;33:1001\u20136.","journal-title":"Int J Obes (Lond)"},{"key":"2185_CR127","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1097\/MS9.0000000000003428","volume":"87","author":"SS Nayak","year":"2025","unstructured":"Nayak SS, Hashemi SM, Patel M, Shafi N, Biswas P, Javankiani S, et al. The impact of weight loss interventions on thyroid function: a systematic review and meta-analysis. Ann Med Surg (Lond). 2025;87:4484\u201397.","journal-title":"Ann Med Surg (Lond)"},{"key":"2185_CR128","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/M14-1456","volume":"162","author":"JB Rugge","year":"2015","unstructured":"Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162:35\u201345.","journal-title":"Ann Intern Med"},{"key":"2185_CR129","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1210\/jc.2009-2798","volume":"95","author":"P Marzullo","year":"2010","unstructured":"Marzullo P, Minocci A, Tagliaferri MA, et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab. 2010;95:3965\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR130","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000494908","volume":"53","author":"R Pasquali","year":"2019","unstructured":"Pasquali R, Oriolo C. Obesity and androgens in women. Front Horm Res. 2019;53:120\u201334.","journal-title":"Front Horm Res"},{"key":"2185_CR131","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jogc.2018.04.030","volume":"40","author":"N Mahutte","year":"2018","unstructured":"Mahutte N, Kamga-Ngande C, Sharma A, et al. Obesity and Reproduction. J Obstet Gynaecol Can. 2018;40:950\u201366.","journal-title":"J Obstet Gynaecol Can"},{"key":"2185_CR132","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.fertnstert.2015.08.018","volume":"104","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2015","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2015;104:1116\u201326.","journal-title":"Fertil Steril"},{"key":"2185_CR133","doi-asserted-by":"publisher","first-page":"627","DOI":"10.5603\/EP.a2022.0047","volume":"73","author":"A Baranowska-Bik","year":"2022","unstructured":"Baranowska-Bik A. Therapy of obesity in women with PCOS using GLP-1 analogues \u2013 benefits and limitations. Endokrynol Pol. 2022;73:627\u201343.","journal-title":"Endokrynol Pol"},{"key":"2185_CR134","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1210\/jc.2006-2274","volume":"92","author":"A Jain","year":"2007","unstructured":"Jain A, Polotsky AJ, Rochester D, et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007;92:2468\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR135","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1210\/jc.2008-2648","volume":"94","author":"RL Robker","year":"2009","unstructured":"Robker RL, Akison LK, Bennett BD, et al. Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. J Clin Endocrinol Metab. 2009;94:1533\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR136","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1210\/jc.2010-2724","volume":"96","author":"P Dandona","year":"2011","unstructured":"Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96:2643\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR137","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/humupd\/dmh035","volume":"10","author":"E Nieschlag","year":"2004","unstructured":"Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 2004;10:409\u201319.","journal-title":"Hum Reprod Update"},{"key":"2185_CR138","first-page":"83","volume":"15","author":"CJ Fernandez","year":"2019","unstructured":"Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism - pathophysiology, clinical implications and management. Eur Endocrinol. 2019;15:83\u201390.","journal-title":"Eur Endocrinol"},{"key":"2185_CR139","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1530\/EJE-12-0955","volume":"168","author":"G Corona","year":"2013","unstructured":"Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829\u201343.","journal-title":"Eur J Endocrinol"},{"key":"2185_CR140","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EC-18-0514","volume":"8","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Podbregar A, Goricar K, et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8:195\u2013202.","journal-title":"Endocr Connect"},{"key":"2185_CR141","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/MED.0000000000000152","volume":"22","author":"R Baudrand","year":"2015","unstructured":"Baudrand R, Vaidya A. Cortisol dysregulation in obesity-related metabolic disorders. Curr Opin Endocrinol Diabetes Obes. 2015;22:143\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2185_CR142","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2337\/diabetes.54.3.872","volume":"54","author":"TC Sandeep","year":"2005","unstructured":"Sandeep TC, Andrew R, Homer NZ, et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872\u20139.","journal-title":"Diabetes"},{"key":"2185_CR143","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12020-013-0112-y","volume":"46","author":"G Tirabassi","year":"2014","unstructured":"Tirabassi G, Boscaro M, Arnaldi G. Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine. 2014;46:370\u201386.","journal-title":"Endocrine"},{"key":"2185_CR144","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1210\/jc.2003-030286","volume":"88","author":"DJ Wake","year":"2003","unstructured":"Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional upregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88:3983\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR145","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1210\/jc.2002-020687","volume":"87","author":"JW Tomlinson","year":"2002","unstructured":"Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab. 2002;87:5630\u201335.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR146","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/oby.2006.92","volume":"14","author":"R Desbriere","year":"2006","unstructured":"Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obes (Silver Spring). 2006;14:794\u20138.","journal-title":"Obes (Silver Spring)"},{"key":"2185_CR147","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/sj.ijo.0803677","volume":"31","author":"L Alberti","year":"2007","unstructured":"Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes. 2007;31:1826\u201331.","journal-title":"Int J Obes"},{"key":"2185_CR148","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2265.2006.02552.x","volume":"65","author":"JH Goedecke","year":"2006","unstructured":"Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol. 2006;65:81\u20137.","journal-title":"Clin Endocrinol"},{"key":"2185_CR149","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jsbmb.2009.12.013","volume":"119","author":"CA Staab","year":"2010","unstructured":"Staab CA, Maser EJ. 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. Steroid Biochem Mol Biol. 2010;119:56\u201372.","journal-title":"Steroid Biochem Mol Biol"},{"key":"2185_CR150","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1568008033340135","volume":"3","author":"H Masuzaki","year":"2003","unstructured":"Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)\u2014a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metab Disord. 2003;3:255\u201362.","journal-title":"Curr Drug Targets Immune Endocr Metab Disord"},{"key":"2185_CR151","doi-asserted-by":"publisher","first-page":"20140020","DOI":"10.1098\/rsfs.2014.0020","volume":"4","author":"K Aschbacher","year":"2014","unstructured":"Aschbacher K, Rodriguez-Fernandez M, van Wietmarschen H, et al. The hypothalamic-pituitary-adrenal-leptin axis and metabolic health: a systems approach to resilience, robustness and control. Interface Focus. 2014;4:20140020.","journal-title":"Interface Focus"},{"key":"2185_CR152","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2020.00059","volume":"11","author":"E Akalestou","year":"2020","unstructured":"Akalestou E, Genser L, Rutter GA. Glucocorticoid metabolism in obesity and following weight loss. Front Endocrinol (Lausanne). 2020;11:59.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2185_CR153","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/ijo.2014.188","volume":"39","author":"A Stomby","year":"2015","unstructured":"Stomby A, Simonyte K, Mellberg C, et al. Diet-induced weight loss has chronic tissue-specific effects on glucocorticoid metabolism in overweight postmenopausal women. Int J Obes. 2015;39:814\u20139.","journal-title":"Int J Obes"},{"key":"2185_CR154","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1210\/jc.2014-4120","volume":"100","author":"CP Woods","year":"2015","unstructured":"Woods CP, Corrigan M, Gathercole L, et al. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). J Clin Endocrinol Metab. 2015;100:1434\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"2185_CR155","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1210\/jc.2009-2472","volume":"95","author":"K Simonyte","year":"2010","unstructured":"Simonyte K, Olsson T, Naslund I, et al. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11 beta-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue. J Clin Endocr Metab. 2010;95:3527\u201331.","journal-title":"J Clin Endocr Metab"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02185-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:02:41Z","timestamp":1784041361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02185-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2185"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02185-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work did not directly involve human or animal subjects; therefore, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}